Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC Recruiting

2023-510506-41-00 Locally advanced, unresectable non-small-cell lung canc 4 2024-04-15
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Locally advanced cervical cancer 5 2024-04-12
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting

2022-501725-21-00 Neuroblastoma 1 2024-04-12
A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors Recruiting

2023-505358-16-00 Advanced Solid Tumors 1 2024-04-11
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting

2022-500305-40-00 Small Lymphocytic Lymphoma 9 2024-04-10
European Larynx Organ Preservation Study (ELOS) Recruiting

2022-502751-61-00 Advanced stage III, IVA, IVB laryngeal or II, III, IVA, 4 2024-04-10
PRIDE – PRotective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma Recruiting

2024-514865-20-00 Glioblastoma 4 2024-04-10
SMILe: Spinal Morphine or Intravenous Lidocaine in robot-assisted upper urologic surgery Recruiting

2023-505941-21-00 Renal or ureter malignancy; Renal or ureter benign tumo 5 2024-04-09
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting

2022-500031-37-00 stage IA/IIA Hodgkin lymphoma 5 2024-04-08
A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina… Recruiting

2022-502272-23-00 Locally advanced unresectable or metastatic androgen re 4 2024-04-08
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Acute myeloid leukemia 4 2024-04-07
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting

2023-505221-14-00 Multiple Myeloma 4 2024-04-04
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa… Recruiting

2023-503208-94-00 Prostate cancer 6 2024-04-04
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting

2023-506759-51-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 7 2024-03-29
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc… Recruiting

2023-506885-30-00 Adult patients with intermediate low or mid rectal aden 5 2024-03-26
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting

2023-508531-30-00 grade 1 glioma/mixed glio-neuronal tumors or pleomorphi 4 2024-03-25
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety,Tolerability, Pharmacoki… Recruiting

2023-507738-26-00 Breast Cancer 9 2024-03-20
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c… Recruiting

2023-506714-43-00 ALK positive Non-Small Cell Lung Cancer 4 2024-03-15